Blueprint Medicines Corp (NAS:BPMC)
$ 95.39 0.82 (0.87%) Market Cap: 6.01 Bil Enterprise Value: 5.83 Bil PE Ratio: 0 PB Ratio: 19.46 GF Score: 81/100

Blueprint Medicines Corp at Goldman Sachs Healthcare Conference Transcript

Jun 14, 2023 / 04:20PM GMT
Release Date Price: $58.76 (+0.79%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good morning. Thanks, everyone, for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're really pleased to have the Blueprint team with us. We have Kate Haviland, CEO; and Fouad Namouni, President of R&D. So Kate, maybe to start with you here. Since assuming the role of CEO, have you implemented any changes in strategy? And how are you thinking of where Blueprint goes on the forward from here?

Kathryn Haviland
Blueprint Medicines Corporation - President, CEO & Director

Yes. So first of all, thank you, Salveen, and the whole Goldman Sachs team for having us here today. It's great to see a bunch of people in the room, and those of us on the webcast, thank you for joining.

It's -- Blueprint, I have joined Blueprint Medicines almost 7.5 years ago. And we started out as a company that had very important but very discrete precision medicine opportunities with our first approval being PDGFR alpha-driven GIST for AVYAKIT in 2020. And where we are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot